柴胡解毒汤联合阿德福韦酯治疗慢性乙型肝炎患者外周血淋巴细胞亚群和细胞因子的变化

doi:10.3969/j.issn.1672-5069.2017.01.010

Abstract

Abstract: Objectives To investigate the changes of peripheral blood T lymphocyte subsets and IL-2 in patients with chronic hepatitis B（CHB） receiving Bupleurum Jiedu decoction combined with adefovir dipivoxil （ADV） therapy. Methods 60 patients with CHB were recruited in our hospital between December 2013 and March 2015. They were treated with Bupleurum Jiedu decoction in group A （n=20）,with ADV in group B （n=20） and with both in group C（n=20）. All regimens lasted for 12 months. Serum HBV markers and IL-2 were detected by ELISA,and T lymphocyte subsets and natural killer cells were detected by flow cytometry. Results At the end of 12-month treatment,the serum HBV DNA loss,ALT normalization rate and HBeAg negative rate in group C were 85.00%,80.00% and 80.00%,much higher than in group A（50.00%,65.00% and 45.00%,respectively） or in group B（65.00%,55.00% and 50.00%,respectively,P<0.05）;the proportion of peripheral CD3⁺T cells and CD4⁺T cells and ratio of CD4⁺/CD8⁺ cells in groups C were（65.2±9.6）%,（28.4±7.2）% and（1.1±0.3）,significantly different as compared to those in group A 【（57.5±8.7）%,（45.7±5.4）% and（1.8±0.6）, respectively or group B（55.7±6.3）%,（23.2±9.5）% and（0.9±0.1）,respectively,P<0.05];the proportion of CD8⁺T cells in group C was （25.3±4.1）%,much lower than in group B [（28.7±4.3） %,P<0.05];the proportion of NK cells in group C was not significantly different as compared to that in group A or in group B（P>0.05）,while serum IL-2 level【（3.6±0.8）ng/mL】 was much higher than in group B【（2.8±0.5）ng/mL,P<0.05】;the increased CD4⁺T cells was positively correlated to serum HBV DNA loss in group A（P<0.05） and the increased CD3⁺T cells, decreased CD8⁺T cells and increased NK cells were positively correlated to serum HBV DNA loss in group C（P<0.05）. Conclusions The application of Bupleurum Jiedu decoction combined with adefovir dipivoxil can adjust lymphocyte dysfunction,break immune tolerance and improve the recovery of liver functions.

Key words: Hepatitis B, Herbal medicine, Adefovir dipivoxil, Peripheral lymphocyte subsets

Xiao Yuzhu.. Changes of peripheral blood T lymphocyte subsets and IL-2 in patients with chronic hepatitis B receiving Bupleurum Jiedu decoction combined with adefovir dipivoxil therapy[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(1): 34-37.

References

[1] Liu XR,Li R,Yu Xl,et al. Hepatitis B virus can be inhibited by DNA methyltransferase 3a via specific zinc-finger-induced methylation of the X promoter. Biochemistry,2014,79（2）:111-123.
[2] Lyu JJ,Yu S,Wang YF,et al. Anti-hepatitis B virus norbisabolane sesquiterpenoids from phyllanthus acidus and the establishment of their absolute configurations using theoretical calculations. J Organ Chem,2014,79（12）:5432-5447.
[3] 黄英男,吴昊. 乙型肝炎肝硬化抗病毒治疗研究进展. 复旦学报（医学版）,2013,40（2）:233-238.
[4] 李庆,武永乐,李冰,等. 慢性乙型肝炎患者外周血调节性B细胞与乙型肝炎病毒DNA定量的相关性.北京医学,2014,36（12）:1056-1057.
[5] He N,Wang F,Ma C,et al. Chemiluminescence analysis for HBV-DNA hybridization detection with magnetic nanoparticles based DNA extraction from positive whole blood samples. J Biomed Nanaotechnol,2013,9（2）:267-273.
[6] 中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南（2015年版）. 实用肝脏病杂志,2016,19（3）：Ⅴ-ⅩⅩⅢ.
[7] Li MR,Xi HL,Wang QH,et al. Kinetics of serum HBsAg in Chinese patients with chronic HBV infection with long-term adefovir dipivoxil treatment. Chin J Med,2014,127（11）:2101-2104.
[8] 胥萍,陈慧,吴敏娟,等. 乙型肝炎患者外周血HBV抗原抗体表达及病毒载量与T细胞亚群检测分析.现代检验医学杂志,2013,28（3）:44-47.
[9] 史贵秀,赵新平,褚建伟,等. 替比夫定对慢性HBV感染孕妇CD4 + CD25 + 调节性T细胞的影响.国际医药卫生导报,2014,20（18）:2811-2815.
[10] 矫淑媛,张学平. HBsAg定量与HBV-DNA联合检测在慢性乙型肝炎中的临床意义.标记免疫分析与临床,2015,22（12）:1245-1247,1213.
[11] Xu L,Yin W,Sun R,et al. Liver type i regulatory T cells suppress germinal center formation in HBV-tolerant mice. Proc Natl Acad Sci USA,2013,110（42）:16993-16998.
[12] 吴杭源,尤德宏.替比夫定对e抗原阳性慢性乙型肝炎患者外周血NK细胞水平的影响. 现代中西医结合杂志,2013,22（6）:621-622.
[13] 卢林,曾令伟. 调节性T淋巴细胞在乙型肝炎慢性化过程中的作用. 重庆医学,2013,42（4）:459-461.
[14] 李松,崔丽安,施伯安,等. 柴胡解毒汤治疗慢性乙型肝炎肝纤维化的临床研究. 陕西中医,2015,36（9）:1136-1137.
[15] 侯珊珊,赵远红. 循经辨治腮腺混合瘤的经验.江苏中医药,2015,47（10）:25-26.
[16] Xu Y,Wu XN,Shi YW,et al. Baseline hepatitis B virus DNA level is a promising factor for predicting the 3rd month virological response to entecavir therapy:A study of strict defined hepatitis B virus Induced cirrhosis. Chin J Med,2015,128（14）:1867-1872.
[17] 祖述臣. 大柴胡汤加减联合西医疗法治疗脑卒中. 吉林中医药,2015,35（11）:1115-1117.
[18] 李娜,马翠翠,李楠,等. “清热解毒、消肿排脓”法联合刺络、中药足浴治疗急性化脓性扁桃体炎疗效观察. 现代中西医结合杂志,2015,24（14）:1510-1512.
[19] Song GJ,Rao HY,Feng B,et al. Association between CISH polymorphisms and spontaneous clearance of hepatitis B virus in hepatitis B extracellular antigen-positive patients during immune active phase. Chin J Med,2014,127（9）:1691-1695.
[20] 赵蕊,赵跃,曲美晶,等. 疏肝解毒汤治疗慢性乙型病毒性肝炎疗效观察. 陕西中医,2014,35（2）:170-171.

Changes of peripheral blood T lymphocyte subsets and IL-2 in patients with chronic hepatitis B receiving Bupleurum Jiedu decoction combined with adefovir dipivoxil therapy

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	chronic hepatitis B Zhu Lingyun, Zhang Maohai Cui Shasha, et al.. Serum IL-12 and IL-18 levels as well as peripheral blood mononuclear cell FOXp3 in patients with [J]. Journal of Practical Hepatology, 2019, 22(6): 816-819.
[2]	Shi Yingying, Wang Yuanxi.. Impact of combination telbivudine and adefovir dipivoxil on renal functions in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 820-823.
[3]	Min Feng, Huang Wenqi, Wu Weibing, et al.. Implications of serum adipocytokine levels in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 824-827.
[4]	patients with chronic hepatitis B Zhang Yingming, Shen Shuang, Tian Fei, et al.. Prediction of response to peginterferon alfa-2a by blood IFNL4 and IL-28B gene polymorphisms in [J]. Journal of Practical Hepatology, 2019, 22(6): 828-831.
[5]	chronic hepatitis B virus carriers Wu Haiyi, Chen Jianxin.. Diagnostic efficacy of four non-invasive diagnostic models in evaluating significant liver fibrosis in [J]. Journal of Practical Hepatology, 2019, 22(6): 832-835.
[6]	Ma Liying, Shen Lijuan.. Efficacy and safety of tenofovir in the treatment of pregnant women with high HBV DNA loads [J]. Journal of Practical Hepatology, 2019, 22(6): 836-839.
[7]	Li Chuanjie, Xu Jing, Wang Liangliang, et al.. Changes of serum HBsAg levels in patients with chronic hepatitis B receiving entecavir treatment [J]. Journal of Practical Hepatology, 2019, 22(6): 928-929.
[8]	Du Keye, Yang Dongliang, Liu Jia. Regulatory T cells in hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 613-616.
[9]	Liao Guichan, Peng Jie, Zhang Xiaoyong. Roles of hepatocytes in intrinsic innate immunity in control of hepatits B virus infection [J]. Journal of Practical Hepatology, 2019, 22(5): 617-619.
[10]	Zhao Xieshan, Wu Chunrong, Wang Chunfeng, et al. Preliminary study on the efficacy of combination of tenofovir and Anluo Huaxian pill in the treatment of patients with HBeAg-negative chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 644-647.
[11]	Tu Jiexia, Wang An’na, Liao Ruoxi. Comparative study of interferon alpha -2b and peginterferon alpha -2a in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 648-651.
[12]	Gao Wei, Hou Yong. Diagnostic efficacy of hepatic fibrosis by liver stiffness measurement in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 652-655.
[13]	Zhang Xu Lei, Yang Qingyu, Han Qiuyu, et al. Short-term efficacy of herbal medicine in treatment of patients with nonalcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2019, 22(5): 660-663.
[14]	Zhu Yucheng, Yan Jiawei, Sun Jingkun, et al. Serum diamine oxidase level in patients with hepatitis B-induced acute-on-chronic liver failure [J]. Journal of Practical Hepatology, 2019, 22(5): 672-675.
[15]	Zhang Mei, Shi Xiuying, Li Linjuan, et al. Hepatic expression of interferon inducible protein -10 in patients with hepatitis B liver cirrhosis and hepatogenic diabetes mellitus [J]. Journal of Practical Hepatology, 2019, 22(5): 688-691.